GlaxoSmithKline Pharmaceuticals Limited
GSK House, Dr. Annie Besant Road,
Worli, Mumbai - 400 030
Tel No: +91 22 2495 9595
Web: www.gsk-india.com
Email: askus@gsk.com

26th November 2026

To,

BSE LIMITED
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400001

THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED
Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (East)
Mumbai - 400051

Dear Sir,

Sub: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to the captioned subject, we would like to inform you that the Company has received Order dated 20th November 2026 from Maharashtra GST authorities, pertaining to the periods April 2020 to March 2021, April 2021 to March 2022 and April 2023 to March 2024, raising a total demand of Rs. 3,18,99,372/- in Maharashtra State. The relevant details to be is disclosed is as under:

Sr no	Particulars	Details
1	Name of the authority	Additional Commissioner, CGST & Central Excise, Appeal II, Mumbai
2	Nature and details of the action(s) taken, initiated or order(s) passed	Appellate Orders dated 20th November 2026 April 2020 to Mar 2021 - Tax Rs. 55,90,716; Interest - Not quantified; Penalty Rs. 55,90,716 (Total demand: Rs. 1,11,81,431) April 2021 to Mar 2022 - Tax Rs. 90,45,908; Interest - Not quantified; Penalty Rs. 90,45,908 (Total demand: Rs. 1,80,91,816) April 2023 to Mar 2024 - Tax Rs. 13,13,062; Interest - Not quantified; Penalty Rs. 13,13,062 (Total demand: Rs. 26,26,124) Total demand: Tax Rs. 1,59,49,686; Interest - Not quantified; Penalty 1,59,49,686 (Total demand: Rs. 3,18,99,372)
3	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	25th November 2026
4	Details of violation(s) / contravention(s) committed or alleged to be committed	Demand on account of alleged non-payment of GST pertaining to export of services
5	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible	No financial impact on the Company. The Company is evaluating the demand order and will take appropriate actions in due course.

Kindly take the same on the record.

Thanking you,

Yours faithfully
For **GlaxoSmithKline Pharmaceuticals Limited**

AJAY AVINASH NADKARNI

Digitally signed by AJAY AVINASH NADKARNI
Date: 2026.11.26 15:26:59 +05'30'

Ajay Nadkarni
Vice President – Administration, Real Estate
& Company Secretary

CIN: L24239MH1924PLC001151